{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:17:35Z","timestamp":1791145055714,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2960,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.exphem.2014.01.006","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T04:15:34Z","timestamp":1390450534000},"page":"360-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications"],"prefix":"10.1016","volume":"42","author":[{"given":"Emmanuel","family":"Pourcelot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Trocme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mondet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Mossuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2014.01.006_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.exphem.2014.01.006_bib2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.exphem.2014.01.006_bib3","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.01.006_bib4","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.01.006_bib5","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.01.006_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00062752-199809000-00004","article-title":"Bleeding and thrombosis in myeloproliferative disorders","volume":"5","author":"Landolfi","year":"1998","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2014.01.006_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.01.006_bib8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2014.01.006_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2014.01.006_bib10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2014.01.006_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2014.01.006_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. 2010","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2014.01.006_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J ClinOncol"},{"key":"10.1016\/j.exphem.2014.01.006_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2014.01.006_bib15","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F","volume":"30","author":"Boissinot","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2014.01.006_bib16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.01.006_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2008.10.002","article-title":"Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling","volume":"340","author":"Chowdhury","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.exphem.2014.01.006_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.27186","article-title":"Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis","volume":"62","author":"Kokkonen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.exphem.2014.01.006_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.leu.2401314","article-title":"Polycythemia vera megakaryocytes but not megakaryocytes from normal controls and patients with smokers polyglobuly spontaneously express IL-6 and IL-6R and secrete IL-6","volume":"13","author":"Wickenhauser","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.01.006_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/cyto.2002.1994","article-title":"Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera","volume":"20","author":"Hermouet","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.exphem.2014.01.006_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajh.10020","article-title":"Soluble angiogenic factors: implications for chronic myeloproliferative disorders","volume":"69","author":"Musolino","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.01.006_bib22","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.01.006_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1538-7836.2004.00689.x","article-title":"Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study","volume":"2","author":"Reitsma","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.exphem.2014.01.006_bib24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s00380-010-0111-3","article-title":"In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction","volume":"26","author":"Poredos","year":"2011","journal-title":"Heart Vessels"},{"key":"10.1016\/j.exphem.2014.01.006_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2141.2002.03245.x","article-title":"Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis","volume":"116","author":"vanAken","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.01.006_bib26","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1371\/journal.pmed.0030334","article-title":"Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study","volume":"3","author":"Christiansen","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.exphem.2014.01.006_bib27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1055\/s-0037-1613858","article-title":"Recurrent venous thrombosis and markers of inflammation","volume":"83","author":"vanAken","year":"2002","journal-title":"Thromb Haemost"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:57Z","timestamp":1759566657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X14000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0301472X14000526"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2014.01.006","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2014.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}